Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,473 INR | -0.38% | +3.44% | +8.59% |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.59% | 1.35B | - | ||
+20.76% | 43.77B | B- | ||
+28.00% | 22.83B | B+ | ||
+20.25% | 15.56B | - | ||
+18.82% | 14.34B | B+ | ||
+55.83% | 12.96B | B | ||
-0.05% | 6.79B | - | - | |
-12.70% | 6.41B | B+ | ||
-8.87% | 5.73B | - | - | |
+14.65% | 5.69B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CAPLIPOINT Stock
- CAPLIPOINT Stock
- Ratings Caplin Point Laboratories Limited